ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, cross-sectional study to monitor the effects of
crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in
children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week
period of time. The goal of this study is to detect changes in PROs and caregiver burden
during treatment for atopic dermatitis of moderate or less severity. The study design will
allow us to correlate PROs and caregiver burden with treatment response and disease
improvement in children.